Dr. Lilja Solnes, Director of the Nuclear Medicine and Molecular Imaging division at Johns Hopkins, describes the mechanisms of Theranostics, a groundbreaking treatment that combines imaging and molecular radiotherapy. With this method, radiopharmaceuticals can be specifically targeted at cancer while leaving most normal tissues alone. Find out more at the Nuclear Medicine Radiotheranostic Center.